Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Queensland Health
Fish and Richardson
UBS
Covington

Generated: August 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,956,600

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,956,600
Title:Ophthalmic drug delivery system containing phospholipid and cholesterol
Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
Inventor(s): Shih; Sheue-Fang (Taipei, TW), Chang; Po-Chun (Taipei, TW), Tseng; Yun-Long (Taipei, TW), Guo; Luke S. S. (South San Francisco, CA), Hong; Keelung (South San Francisco, CA)
Assignee: Taiwan Liposome Co. Ltd. (Taipei, TW) TLC Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:12/538,435
Patent Claims:1. An ophthalmic drug delivery system, comprising (a) a delivery vehicle suitable for vitreous humor drug delivery consisting essentially of a phospholipid or a mixture of phospholipids selected from the group consisting of DOPC, POPC, SPC, EPC, PEG-DSPE and DOPG and cholesterol, wherein cholesterol is present in an amount of 10-33 mole percent relative to the delivery vehicle; and (b) an antagonist specific to VEGF selected from a group consisting of an antibody specific to VEGF, a VEGF receptor, a nucleic acid or a small molecule; wherein 50-90% of the antagonist is in non-associated form, the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-80 to 1 and the life time of the antagonist is extended in the vitreous humor.

2. The ophthalmic drug delivery system of claim 1, wherein the antibody specific to VEGF is a naturally occurring immunoglobulin, a functional fragment thereof, a humanized antibody, a chimeric antibody, a diabody or a single chain antibody.

3. The ophthalmic drug delivery system of claim 1, wherein the antibody specific to VEGF is Avastin.

4. The ophthalmic drug delivery system of claim 1, wherein the antibody is a Fab, Fab', F(ab).sub.2 or F(ab').sub.2 fragment.

5. The ophthalmic drug delivery system of claim 1, wherein the phospholipid is a mixture of a first phospholipid and a second phospholipid, the first phospholipid being DOPC, POPC, SPC, or EPC and the second phospholipid being PEG-DSPE or DOPG.

6. The ophthalmic drug delivery system of claim 5, wherein the first phospholipid is DOPC and the second phospholipid is DOPG.

7. The ophthalmic drug delivery system of claim 6, wherein, in the delivery vehicle, the mole percent of DOPC is 29.5% to 90%, the mole percent of DOPG is 3% to 37.5%.

8. The ophthalmic drug deliver system of claim 6, wherein the ratio of DOPC:DOPG:cholesterol is 56.25-72.5:7.5-18.75:20-25 by mole percent.

9. The ophthalmic drug delivery system of claim 7, wherein the antagonist specific to VEGF is Avastin.

10. The ophthalmic drug delivery system of claim 8, wherein the antagonist specific to VEGF is Avastin.

11. The ophthalmic drug delivery system of claim 9, wherein 60-90% of the antagonist is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-40 to 1.

12. The ophthalmic drug delivery system of claim 10, wherein 60-90% of the antagonist is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-40 to 1.

13. The ophthalmic drug delivery system of claim 1, further comprising an anti-inflammation molecule.

14. The ophthalmic drug delivery system of claim 13, wherein the anti-inflammation molecule is a corticosteroid.

15. The ophthalmic drug delivery system of claim 14, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, fluocinolone, prednisolone, prednisone, triamcinolone, methylprednisolone, dexamethasone, and betamethasone.

16. The ophthalmic drug delivery system of claim 1, wherein the delivery vehicle and the antagonist are admixed and in lyophilized form.

17. The ophthalmic drug delivery system of claim 1, wherein the delivery vehicle and the antagonist are separate.

18. The ophthalmic drug delivery system of claim 17, wherein the delivery vehicle is in lyophilized form.

19. A drug delivery system, comprising (a) a delivery vehicle suitable for vitreous humor drug delivery consists essentially of a phospholipid or a mixture of phospholipids selected from the group consisting of DOPC, POPC, SPC, EPC, PEG-DSPE and DOPG, and cholesterol, wherein cholesterol is present in an amount of 10-33 mole percent relative to the delivery vehicle; and (b) one or more therapeutic agents to the eye; wherein 50-90% of the therapeutic agent to the eye is in non-associated form, the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-80 to 1 and the life time of the therapeutic agent is extended in the vitreous humor.

20. The drug delivery system of claim 19, wherein the therapeutic agent to the eye is an antagonist specific to VEGF.

21. The drug delivery system of claim 20, wherein the antagonist specific to VEGF is an antibody specific to VEGF, a VEGF receptor, a nucleic acid or a small molecule.

22. The drug delivery system of claim 20, wherein the antibody specific to VEGF is a naturally occurring immunoglobulin, a functional fragment thereof, a humanized antibody, a chimeric antibody, a diabody or a single chain antibody.

23. The drug delivery system of claim 20, wherein, the antibody specific to VEGF is Avastin.

24. The drug delivery system of claim 20, wherein the antibody specific to VEGF is a Fab, Fab', F(ab).sub.2 or F(ab').sub.2 fragment.

25. The drug delivery system of claim 19, wherein the therapeutic agent to the eye is an anti-inflammation molecule.

26. The drug delivery system of claim 25, wherein the anti-inflammation molecule is a corticosteroid.

27. The drug delivery system of claim 19, wherein the delivery vehicle and the therapeutic agent to the eye are admixed and in lyophilized form.

28. The drug delivery system of claim 19 wherein the delivery vehicle and the therapeutic agent to the eye are separate.

29. The drug delivery system of claim 28, wherein the delivery vehicle is in lyophilized form.

30. The drug delivery system of claim 19, wherein the phospholipid is a mixture of a first phospholipid and a second phospholipid, the first phospholipid being DOPC, POPC, SPC, or EPC and the second phospholipid being PEG-DSPE or DOPG.

31. The drug delivery system of claim 30, wherein the first phospholipid is DOPC and the second phospholipid is DOPG.

32. The drug delivery system of claim 31, wherein, in the delivery vehicle, the mole percent of DOPC is 29.5% to 90%, the mole percent of DOPG is 3% to 37.5%.

33. The drug deliver system of claim 31, wherein the ratio of DOPC:DOPG:cholesterol is 56.25-72.5:7.5-18.75:20-25 by mole percent.

34. The drug delivery system of claim 32, wherein 60-90% of the therapeutic agent to the eye is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-40 to 1.

35. The drug delivery system of claim 33, wherein 60-90% of the therapeutic agent to the eye is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-40 to 1.

36. The ophthalmic drug delivery system of claim 1, wherein the cholesterol is present in an amount of 25 mole percent relative to the delivery vehicle.

37. The drug delivery system of claim 19, wherein the cholesterol is present in an amount of 25 mole percent relative to the delivery vehicle.

38. The drug delivery system of claim 26, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, fluocinolone, prednisolone, prednisone, triamcinolone, methylprednisolone, dexamethasone, and betamethasone.

Details for Patent 8,956,600

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Taiwan Liposome Co. Ltd. (Taipei, TW) TLC Biopharmaceuticals, Inc. (South San Francisco, CA) 2037-10-24 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Taiwan Liposome Co. Ltd. (Taipei, TW) TLC Biopharmaceuticals, Inc. (South San Francisco, CA) 2037-10-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Express Scripts
Cipla
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.